Zydus Life noted that population-scale studies show high rates of bone involvement, affecting 50-70% of advanced breast or ...

Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...

Cancer drug developer Immutep has landed a major offshore commercialisation deal worth $30 million upfront and as much as ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...

Sydney-based Immutep and Dr Reddy’s Laboratories have inked an exclusive licensing agreement through their arms for the ...

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Vietnam has approved the Russian cancer drug Pembroria, offering patients a new, cost‑effective treatment option. The move follows deeper health cooperation with Russia and comes as cancer cases in ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...

The standing ovation for Keytruda and Padcev in metastatic bladder cancer at the 2023 European Society for Medical Oncology (ESMO) Congress still echoes, and, now, the pair from Merck & Co., Pfizer ...